Pharmaceutical Technology

MARCH 3, 2023

Bristol Myers Squibb has secured complete marketing authorisation from the European Commission (EC) for Reblozyl (luspatercept) to treat anaemia in adult patients with non-transfusion dependent (NTD) beta-thalassemia. The post Bristol Myers Squibb secures EC marketing approval for anemia therapy appeared first on Pharmaceutical Technology.

Marketing 147

Marketing Clinical Development Development 147

Drug Discovery World

MAY 20, 2024

Glucagon-like peptide-1 (GLP-1) receptor agonist sales for the type 2 diabetes and obesity markets are forecast to reach over $125 billion in the seven major markets (7MM) by 2033, according to analysts GlobalData. But there is an opportunity for new players to join the race, as the market is vast.

Marketing 52

Marketing Sales Doctors Doctor 52

XTalks

OCTOBER 4, 2023

Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.

Marketing 105

Marketing Development Drugs Gene Therapy 105

BioPharma Reporter

MARCH 3, 2021

The number of advanced therapy medicinal product (ATMP) clinical trials in the UK continues to increase year on year with 154 ongoing trials observed in 2020, demonstrating the appeal of that market for the clinical development of ATMPs, shows a new report.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

Drug Discovery World

SEPTEMBER 28, 2023

Both GTPs and GMPs must be followed to get cell-based advanced therapies or tissue-based therapy products to market. Can a manufacturer of a cell or gene therapy switch suppliers midstream in clinical development? What are the costs and time delays of switching suppliers later in clinical development?

Marketing 52

Marketing Gene Therapy Clinical Development Gene 52

Worldwide Clinical Trials

DECEMBER 7, 2023

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture.

Clinical Development 341

Clinical Development Clinical Trials Clinical Trials Trials 341

BioTech 365

JANUARY 6, 2021

CAEL-101: A Fibril-reactive Monoclonal Antibody (mAb) that is Currently in Phase 3 Clinical Development – Global Emerging Insight and Market Forecasts 2020-2030 – ResearchAndMarkets.com CAEL-101: A Fibril-reactive Monoclonal Antibody (mAb) that is Currently in Phase 3 Clinical Development – Global … Continue reading → (..)

Clinical Development 40

Clinical Development Antibody Development Marketing 40

Intouch Solutions

MAY 1, 2023

Both McKinsey (2014) and Deloitte (2022) emphasize that market access strategy and execution – a life sciences company’s ability to demonstrate clinical and economic evidence, negotiate with healthcare access stakeholders, and enable affordable and timely product fulfillment for appropriate patients – are critical to a drug’s success or failure.

Marketing 75

Marketing Life Science Production Clinical Trials 75

Outsourcing Pharma

SEPTEMBER 29, 2023

Chinese biopharmaceutical company, Hutchmed Limited, has announced today (Friday September 29) that it has taken a step towards bringing a colon and rectum cancer drug to a third market.

Marketing 88

Marketing Drugs Clinical Development Development 88

Pharmaceutical Technology

JULY 18, 2022

There have recently, however, been some notable developments towards improving the care of bronchiectasis patients. These include the ongoing clinical development of AstraZeneca’s Fasenra (benralizumab), Insmed’s brensocatib and Novartis’ icenticaftor (QBW251).

Marketing 147

Marketing Trials Development Protein 147

Drug Discovery World

JUNE 1, 2023

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

OCTOBER 20, 2023

Protocol amendments slow down clinical development and are extremely costly. The post Free clinical trial health check to bring drugs to market faster appeared first on Drug Discovery World (DDW). The average Phase III protocol experiences 3.3 months of implementation time.

Clinical Trials 64

Clinical Trials Clinical Trials Trials Marketing 64

Outsourcing Pharma

JULY 24, 2023

Phesi, a global provider of patient-centric data analytics, has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date.

Clinical Development 77

Clinical Development Clinical Trials Clinical Trials Development 77

pharmaphorum

MAY 3, 2022

Belsomra’s first-to-market advantage in the US hasn’t however translated into big annual sales, which have stayed planted just over the $300 million mark since 2019. The class as a whole is, however, trying to break into a low-cost generic market, and almost inevitably is facing pushback from payers.

Marketing 78

Marketing Drugs Sales Pharma Companies 78

Pharmaceutical Technology

APRIL 21, 2023

Biotechnology company Enveda Biosciences has raised $51m in equity financing in a Series B1 round to advance several drug candidates to clinical development. Enveda Biosciences intends to use the additional financing to advance several candidates derived from its drug discovery platform to clinical development in 2023 and 2024.

Clinical Development 147

Clinical Development Development Drugs Medicine 147

Worldwide Clinical Trials

APRIL 15, 2024

The Advantages of Midsize CROs In contrast to large CROs, midsize CROs like Worldwide Clinical Trials offer a unique value proposition to the market. To gain deeper insights into this pivotal shift and how it can benefit your clinical development strategy, we invite you to download our full industry survey report.

Clinical Trials 130

Clinical Trials Clinical Trials Clinical Development Clinical Research 130

The Pharma Data

SEPTEMBER 22, 2020

Trial design and other details are being evaluated and a comprehensive update on the overall Novartis SMA clinical development program will be provided at a future time following further discussions with health authorities. This guidance provides clarity on the path to registration for AVXS-101 IT.

Clinical Development 52

Clinical Development Gene Therapy Development Gene 52

Roots Analysis

FEBRUARY 20, 2024

This clinical condition impacts individuals of all ages and backgrounds, but it often goes undiagnosed or overlooked, affecting the individuals’ overall quality of life and well-being. In this article, we have highlighted details on Sleep Apnea Devices Market.

Marketing 40

Marketing Development Clinical Development Drugs 40

Delveinsight

SEPTEMBER 13, 2021

DelveInsight estimates that the present Iron deficiency anemia therapy market is heavily reliant on off-label generics and over-the-counter drugs. Companies like MegaPro Biomedical [MPB-1514 (IOP Injection)] and Nemysis [IDAX (IHAT-02)] are evaluating their novel therapeutic agents in different stages of clinical development.

Marketing 69

Marketing Clinical Development Development Drugs 69

Intouch Solutions

FEBRUARY 23, 2023

Historically, the pharmaceutical industry is economically sturdy, but three things are not: patients’ household budgets, marketing department budgets, and small-company budgets. Let’s talk about the current economic uncertainty and what it means for pharma marketers. What does this mean for pharma marketers? Risks to forecasts.

Marketing 52

Marketing Branding Life Science Clinical Trials 52

Intouch Solutions

FEBRUARY 23, 2023

Historically, the pharmaceutical industry is economically sturdy, but three things are not: patients’ household budgets, marketing department budgets, and small-company budgets. Let’s talk about the current economic uncertainty and what it means for pharma marketers. What does this mean for pharma marketers? Risks to forecasts.

Marketing 52

Marketing Branding Life Science Clinical Trials 52

Pharmaceutical Technology

OCTOBER 21, 2022

Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.

Development 278

Development Production Licensing Licensing 278

Delveinsight

MARCH 1, 2021

Thus, it can be conveniently said that the Rare disease market, which was once barren land has now become fertile ground. First and foremost, the regulatory agencies were ready and willing, with ornaments in hand to decorate the Rare disease market with novel therapies. While more than 150 orphan drugs have been approved in the EU.

Marketing 52

Marketing Clinical Trials Clinical Trials Drugs 52

Outsourcing Pharma

SEPTEMBER 28, 2023

Calliditas Therapeutics says it is optimistic about getting full marketing authorization for a drug to treat primary IgA nephropathy (IgAN) after submitting a request to the European Medicines Agency (EMA).

Marketing 52

Marketing Drugs Medicine Clinical Development 52

Outsourcing Pharma

MAY 4, 2023

Sam Whittaker is founder, and CEO of multiple clinical trial technology companies, including Greenphire and Mural Health.

Clinical Development 52

Clinical Development Clinical Trials Clinical Trials Development 52

pharmaphorum

JANUARY 31, 2022

Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new clinical trial of its mRNA-based candidate DS-5670 that focuses on its use as a booster dose. The Japanese group says it hopes to complete clinical development of the vaccine and bring it to market in Japan before the end of the year.

Marketing 73

Marketing Vaccination Vaccine Antibody 73

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1.

Clinical Development 52

Clinical Development Medicine Development Containment 52

Delveinsight

SEPTEMBER 20, 2021

The Onychomycosis treatment market offers several options, including oral antifungals, topical antifungals, and devices. Three major Topical treatments are currently on the market with two of them being approved as late as 2014 by the US FDA. Penlac (Valeant Pharmaceuticals, Inc.), These 250mg tablets are taken once a day for 12 weeks.

Marketing 74

Marketing Cosmetics Drug Delivery Clinical Development 74

Pharma Mirror

JANUARY 30, 2022

Ben Beckley, Global Lead at EmerGENE explores the market challenges holding back Cell and Gene Therapy (C&GT) from taking its place as an established treatment area. Some 3,366 treatments are currently in preclinical and clinical development[1]. Some 3,366 treatments are currently in preclinical and clinical development[1].

Gene Therapy 130

Gene Therapy Gene Clinical Development Marketing 130

Pharmaceutical Technology

MAY 29, 2023

FivepHusion has collaborated with Treehill Partners and Syneos Health to strategically progress development and commercialisation of its chemotherapeutic formulation Deflexifol in markets across the globe. Syneos will support the commercialisation and clinical development capabilities of FivepHusion.

Business Development 130

Business Development Development Marketing Clinical Development 130

The Pharma Data

NOVEMBER 29, 2020

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. . ” About Ascletis.

Clinical Development 40

Clinical Development Development Clinical Trials Clinical Trials 40

Pharmaceutical Technology

FEBRUARY 14, 2023

Under the deal, Corbus Pharmaceuticals will have exclusive rights to develop and commercialise CRB-701 in Canada, Australia, the UK, the EU (including the European Free Trade Area), and the US, while CSPC will retain SYS6002’s rights in the remaining markets. According to the agreement, CSPC will receive a $7.5m

Antibody 130

Antibody Drugs Clinical Development Licensing 130

Delveinsight

JULY 30, 2021

The primary goal to achieve in the Crohn’s disease therapeutics market, to date, remains the reduction of inflammation that triggers signs and symptoms and improvement of long-term prognosis. However, the market growth is expected to face a threat from an inescapable entry of biosimilars in the approaching years.

Marketing 74

Marketing Drug Delivery Development Clinical Trials 74

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. This includes an upfront payment of $2m from AstraZeneca.

Development 264

Development Gene Expression Licensing Licensing 264

Pharmaceutical Technology

JUNE 19, 2023

Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market. Laurus Labs will be responsible for launching these products in India and emerging markets.

Gene Therapy 246

Gene Therapy Gene Production Pharma Companies 246

Pharmaceutical Technology

AUGUST 16, 2022

Gilead Sciences has entered an agreement with Everest Medicines to acquire complete rights to develop and market Trodelvy (sacituzumab govitecan) in Greater China, Singapore, South Korea, Philippines, Vietnam, Thailand, Indonesia, Mongolia and Malaysia.

Marketing 255

Marketing Medicine Clinical Development Development 255

Drug Discovery World

JANUARY 11, 2024

They are called: mRNA technology may hold the future for a cytomegalovirus vaccine ; Predictive diagnostics: closing the precision medicine gap ; and FAIR Game: making data work harder in the race to market. The post New podcast: Revolutionary technology for drug discovery and development appeared first on Drug Discovery World (DDW).

Development 59

Development Drugs Genome Genomics 59